High Flow Nasal Cannula in Immunocompromised Patient With Acute Respiratory Failure
High Flow Nasal Cannula, Non Invasive Ventilation, Acute Respiratory Failure
About this trial
This is an interventional prevention trial for High Flow Nasal Cannula focused on measuring High flow nasal cannula, ., Non invasive ventilation
Eligibility Criteria
Inclusion Criteria:
- . Inclusion criteria includes admitted immunocompromised patient to ICU with acute hypoxemic respiratory failure (ARF).
- Hematological malignancies.
- Post bone marrow transplantation
Exclusion Criteria:
- Need of emergency intubation.
patient with deterioration of conscious level with hypoxemia with FiO2 less than 90% in spite of maximum O2 support.
- hemodynamic instability with need of vasoconstrictor support.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
High flow nasal cannula (HFNC) group
Non invasive ventilation (NIV) group
HFNC group will receive immediate connection to HFNC with a flow of 60L/min, and FIO2 adjusted to have SpO2 of 92% or more, through a heated humidifier and a oxygen blender of the same machine. In case of patient intolerance to high flow, flow will be diminished to the highest tolerated by the patient. Patients will be encouraged to have their mouth closed during HFNC to augment positive end expiratory pressure (PEEP) created by high flow.
NIV group, patients will be connected to ICU ventilatoron NIV mode for at least 4 hours, through a NIV continuous positive airway pressure (CPAP)mask with ventilator settings; pressure support (PS) level of 8 cmH2O and PEEP level of 5 cmH2O,which can be increased to 10 cmH2O to maintain tidal volume between 6-8 ml/Kg and FiO2 adjusted to keep SpO2 equal or more than 92%.At least patient will be on NIV for 12 hours during the day, alternating with Venturi mask 10-15 L/min to keep FiO2 equal or more than 92%.